Yes. SMSbiotech has initiated Phase 1 clinical trials evaluating the safety of its SMS cell therapy in COPD patients.

In clinical studies, SMS cells are delivered directly to the lungs using a nebulizer to support localized tissue regeneration.

SMSbiotech’s approach is based on Small Mobile Stem cells, which are distinct from traditional stem cells and designed for scalable and targeted regenerative therapies.

SMSbiotech is headquartered in San Diego, California, United States.

SMSbiotech is exploring veterinary regenerative applications where SMS cell technology may support tissue healing in animals.

Yes. SMSbiotech works with scientific and clinical partners to advance its regenerative medicine research and development efforts.

SMSbiotech is a San Diego-based biotechnology company developing regenerative medicine solutions using its patented Small Mobile Stem cell platform.

SMSbiotech uses proprietary methods to isolate and expand SMS cells, enabling interaction with regenerative pathways to support tissue repair.

SMSbiotech focuses on chronic and degenerative conditions including COPD, lung fibrosis, orthopedic injuries, and other unmet medical needs.

Small Mobile Stem (SMS) cells are a novel adult human stem cell identified by SMSbiotech with regenerative potential and scalable bio-manufacturing capability.